I graduated from Birmingham University, also completing an Intercalated BSc in the History of Medicine at University College London before training as physician in the West Midlands. Once I decided to specialise in Oncology I completed my training at the Royal Free Hospital and then as a Specialist Registrar in Clinical Oncology on the Oxford Clinical Oncology training scheme.
I have extensive experience in the management of acutely unwell cancer patients, with a weekly session dedicated to “Acute Oncology”. I am the malignant spinal cord compression clinical lead at the Royal Berkshire Hospital in Reading. I am also an Educational Supervisor to Core Medical trainees.
I am a core member of the Upper Gastrointestinal Cancer Multi-Disciplinary Teams and Cancer of Unknown Primary Multi-Disciplinary Teams at both the Royal Berkshire Hospital, Reading and Wexham Park Hospital, Slough. I attend the Oxford Oesophago-gastric and Hepato-biliary Multi-Disciplinary Team meetings on a weekly basis via video-conference and have a strong working relationship with the Oxford teams.
I completed an original research project for my MSC in Oncology on the role of PET-CT in the pre-operative staging of gastric cancer.
I spent 3 years as a Clinical Research Fellow at the Gray Institute of Radiation Oncology and Biology, the University of Oxford, undertaking independent research towards a higher research qualification (DPhil) in Radiobiology. The clinical element of the research explored the role of imaging to measure tumour vascular parameters in response to radiotherapy given before or alongside radio-sensitising drugs in the context of two radiotherapy clinical trials in colorectal cancer. I was also involved in recruitment and trial management for the ARCII trial, a Phase II trial evaluating the addition of a radiosensitiser called Nelfinavir to chemo-radiotherapy for locally advanced pancreatic cancer.
I have been involved in recruitment to numerous national trials. I am currently a co-investigator for the ADD-ASPIRIN trial, which is recruiting patients with resected gastro-oesophageal cancer at the Royal Berkshire Hospital in Reading. I am in the process of setting up the SCOPE-2 trial (a Study of Chemo-radiotherapy in Oesophageal Cancer with PET-CT and dose escalation) as Principal Investigator at the Royal Berkshire Hospital. I am also the Principal Investigator for a commercial study comparing second-line chemotherapy with immunotherapy for oesophageal cancer.
Esme J. Hill, Monica Enescu, Nicholas West, Jamie M. Franklin, Kwun-Ye Chu, Jun Li, Deborah Whittington, Thomas P. Macgregor, Shazad Ashraf, Claire Blesing, Somnath Mukherjee, Margaret Betts, Andrew Slater, Ewan M. Anderson, Gina Brown, Julia A. Schnabel, Mike Partridge, Philip Quirke and Ricky A. Sharma. Oral nelfinavir before and during radiation therapy for rectal cancer: Changes in tumor perfusion and correlation between tissue and radiological markers of response. Journal of Clinical Oncology, 2014, Vol 32, Supplement 3, 491
Esme Hill, Naseer Qayum, Thomas Brunner, Phil Quirke, W. Gillies McKenna, Ricky A. Sharma. Poster Abstract 1050 Changes in perfusion induced by nelfinavir and radiotherapy: Translation to a phase I-II clinical trial. Radiation Oncology 2011; 99 (Supplement 1); S391
Hill EJ, Bradley K. Abstract: The Utility of PET-CT in the Pre-operative Staging of Gastric Cancer. Annals of Oncology 2010(S 6).
Hill EJ, Robert C, Franklin JM, West N, MacGregor TP, Chu KY, Boyle L, Blesing C, Wang LM, Mukherjee S, Anderson EM, Brown G, Dutton S, Love SV, Schnabel JA, Quirke P, Muschel R, Mckenna WG, Partridge M, Sharma RA. Clinical Trial of Oral Nelfinavir before and during Radiation Therapy for Advanced Rectal Cancer. Clinical Cancer Research, 2016; 22(8):1922-31.
Charles J Dearman, Esme J Hill, Jamie M Franklin, Greg P Sadler, Lai Mun Wang, Michael A Silva, Ricky A Sharma. Management of a thyroid incidentaloma in a patient with cancer: a case report. International Medical Case Reports Journal, 2015; 8, 247-249.
Stephanie B Hatch, Lonnie P Swift, Simona Caporali, Rebecca Carter, Esme J Hill, Thomas P MacGregor, Stefania D'Atri, Mark R Middleton, Peter J McHugh and Ricky A Sharma XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: Suitability as a biomarker for patient selection. International Journal of Cancer, 2014; 134(6):1495-503
Adams E, Hill EJ, Watson E. Fertility preservation in cancer survivors: a national survey of oncologists' current knowledge, practice and attitudes. British Journal of Cancer 2013, 108 (8);1602-15
Wang LM, Jani AR, Hill EJ, Sharma RA. Anatomical basis and histopathological changes resulting from selective internal radiotherapy for liver metastases. Journal of Clinical Pathology 2013, 66(3), 205-11
M Enescu, M Bhushan, EJ Hill, J Franklin, EM Anderson, RA Sharma, JA Schnabel, pCT derived arterial input function for improved pharmacokinetic analysis of longitudinal dce-MRI for colorectal cancer, Proceedings of SPIE Medical Imaging 2013
Hill EJ, Nicolay NH, Middleton MR, Sharma RA. Oxaliplatin as a radiosensitiser for upper and lower GI tract malignancies: what have we learned from a decade of translational research? Critical Reviews in Oncology & Haematology 2012 83(3): p. 353-87.
Hill EJ, Sharma RA. Multi-modality therapy of hepatic metastases from colorectal carcinoma: optimal combination of systemic chemotherapy with radio-embolization. Journal of Nuclear Medicine & Radiation Therapy 2011; 2: 108 ePub doi: 10.4172/2155-9619.1000108
Hill EJ, Clift AK, Sharma RA. Principles for Combining Radioembolisation with Systemic Chemotherapy for Metastatic Colorectal Cancer. Interventional Radiology in Cancer, Chapter 14, 2013
Royal College of Radiologists Ross Prize for best proffered paper at the National Cancer Research Institute Conference in Liverpool (2013).
British Association of Cancer Research Travel Award for high quality abstract submission to the BACR conference (2013).
Oxfordshire Health Services Research Committee Fellowship Grant (awarded 2010)
Nil